Would you ever re-treat recurrent ovarian cancer with mirvetuximab soravtansine if the patient responded to it in the past (e.g., more than 6 months ago)?
What is your general philosophy when discontinuing and/or switching chemotherapy in the recurrent setting?
Community PollStarted
In patients with platinum-resistant ovarian cancer, do you re-treat with chemotherapy agents patients have responded to in the past?
85 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Gynecologic Oncology · Cooper Medical School of Rowan University
Answered on
As far as I know, there is no data on the repeat use of mirvetuximab for women who have progressed on prior treatment. I would tend to use cytotoxic therapy in this setting, but if the patient tolerated it well previously and has a good performance status, a short trial of repeat mirvetuximab seems ...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Gynecologic Oncology · Texas Oncology-The Woodlands
Answered on
Agree with Dr. @Dr. First Last. Discontinuation due to progression is probably different from discontinuation due to other events, especially if there was documentation of response. I have personally retreated patients with FRa high expression with mirvetuximab and discontinued treatment due to some...
Join for free or sign in to see the full answer